A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics-Reference-Cited by-同舟云学术

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics

Published:2014-09 Issue:1 Volume:154 Page:37-46
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Casulo Carla,Vose Julie M.,Ho William Y.,Kahl Brad,Brunvand Mark,Goy Andre,Kasamon Yvette,Cheson Bruce,Friedberg Jonathan W.

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference42 articles.

1. Ten years of rituximab in NHL;Winter;Expert Opin. Drug Saf.,2009

2. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy;Vacchelli;Oncoimmunology,2014

3. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma;Maloney;J. Clin. Oncol.,1997

4. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma;Maloney;Blood,1997

5. Pharmacokinetics of rituximab and its clinical use: thought for the best use?;Cartron;Crit. Rev. Oncol. Hematol.,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic options for rituximab-resistant patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

2. Immunotherapy in indolent Non-Hodgkin's Lymphoma;Leukemia Research Reports;2022

3. Therapeutic Antibodies and Immunologic Conjugates;Abeloff's Clinical Oncology;2020

4. Impact of obinutuzumab alone and in combination for follicular lymphoma;Blood and Lymphatic Cancer: Targets and Therapy;2017-10

5. Obinutuzumab: what is there to learn from clinical trials?;Blood;2017-08-03